Biomedical Engineering Reference
In-Depth Information
32. Waldo G, Standish B, Berendzen J, Terwilliger T. (1999) Rapid
protein-folding assay using green fluorescent protein. Nat.
Biotechnol. 17, 691-695.
33. Maeda Y, Ueda H, Kazami J, Kawano G, Suzuki E, Nagamune
T. (1997) Engineering of functional chimeric protein G-
Vargula luciferase. Anal. Biochem. 249, 147-152.
34. Arai R, Ueda H, Kitayama A, Kamiya N, Nagamune T. (2001)
Design of the linkers which effectively separate domains of a
bifunctional fusion protein. Protein Eng. 14, 529-532.
35. Arai R, Wriggers W, Nishikawa Y, Nagamune T, Fujisawa T.
(2004) Conformations of variably linked chimeric proteins
evaluated by synchrotron X-ray small-angle scattering.
Proteins 57, 829-838.
36. Marqusee S, Baldwin RL. (1987) Helix stabilization by
Glu-
Lys
รพ
salt bridges in short peptides of de novo design.
Proc. Natl. Acad. Sci. USA 84, 8898-8902.
37. Werner S, Marillonnet S, Hause G, Klimyuk V, Gleba Y. (2006)
Immunoabsorbent nanoparticles based on a tobamovirus
displaying protein A. Proc. Natl. Acad. Sci. USA 103,
17678-17683.
38. Takamatsu N, Watanabe Y, Yanagi H, Meshi T, Shiba T, Okada
Y. (1990) Production of enkephalin in tobacco protoplasts using
tobacco mosaic virus RNA vector. FEBS Lett. 269, 73-76.
39. Turner S, Russell G, Williamson M, Guest J. (1993) Restruc-
turing an interdomain linker in the dihydrolipoamide acetyl-
transferase component of the pyruvate dehydrogenase complex
of Escherichia coli. Protein Eng. 6, 101-108.
40. Erni B. (1989) Glucose transport in Escherichia coli. FEMS
Microbiol. Rev. 5, 13-23.
41. Bhandari D, Levine B, Trayer I, Yeadon M. (1986)
1
H-NMR
study of mobility and conformational constraints within the
proline-rich N-terminal of the LC1 alkali light chain of skeletal
myosin. Correlation with similar segments in other protein
systems. Eur. J. Biochem. 160, 349-356.
42. Evans J, Levine B, Trayer I, Dorman C, Higgins C. (1986)
Sequence-imposed structural constraints in the TonB protein of
E. coli. FEBS Lett. 208, 211-216.
43. Morris A, MacArthur M, Hutchinson E, Thornton J. (1992)
Stereochemical quality of protein structure coordinates. Pro-
teins 12, 345-364.
44. McCormick A, Thomas M, Heath A. (2001) Immunization
with an interferon-gamma-gp120 fusion protein induces
enhanced immune responses to human immunodeficiency
virus gp120. J. Infect. Dis. 184, 1423-1430.
45. Chen X, Bai Y, Zaro J, Shen WC. (2010) Design of an in vivo
cleavable disulfide linker in recombinant fusion proteins.
Biotechniques 49, 513-518.
46. Schulte S. (2009) Half-life extension through albumin fusion
technologies. Thromb. Res. 124Suppl. 2, S6-8.
47. Vessillier S, Adams G, Chernajovsky Y. (2004) Latent cyto-
kines: development of novel cleavage sites and kinetic analysis
of their differential sensitivity to MMP-1 and MMP-3. Protein
Eng. Des. Sel. 17, 829-835.
48. Wakefield LM, Winokur TS, Hollands RS, Christopherson
K, Levinson AD, Sporn MB. (1990) Recombinant latent
transforming growth factor beta 1 has a longer plasma
half-life in rats than active transforming growth factor
beta 1, and a different tissue distribution. J. Clin. Invest.
86, 1976-1984.
49. Martel-Pelletier J, Welsch DJ, Pelletier JP. (2001) Metallopro-
teases and inhibitors in arthritic diseases. Best Pract. Res. Clin.
Rheumatol. 15, 805-829.
50. Lampert K, Machein U, Machein MR, Conca W, Peter HH,
Volk B. (1998) Expression of matrix metalloproteinases and
their tissue inhibitors in human brain tumors. Am. J. Pathol.
153, 429-437.
51. Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR.
(1998) Matrix metalloproteinases and diseases of the CNS.
Trends Neurosci. 21, 75-80.
52. Leppert D, Lindberg RL, Kappos L, Leib SL. (2001) Matrix
metalloproteinases: multifunctional effectors of inflammation
in multiple sclerosis and bacterial meningitis. Brain Res. Rev.
36, 249-257.
53. Pepinsky RB, LePage DJ, Gill A, Chakraborty A, Vaidyana-
than S, Green M, et al. (2001) Improved pharmacokinetic
properties of a polyethylene glycol-modified form of inter-
feron-beta-1a with preserved in vitro bioactivity. J. Pharm.
Exp. Ther. 297, 1059-1066.
54. Peng KW, Morling FJ, Cosset FL, Murphy G, Russell SJ.
(1997) A gene delivery system activatable by disease-
associated matrix metalloproteinases. Hum. Gene Ther. 8,
729-738.
55. Nagase H, Fields GB. (1996) Human matrix metalloproteinase
specificity studies using collagen sequence-based synthetic
peptides. Biopolymers 40, 399-416.
56. Liu S, Netzel-Arnett S, Birkedal-Hansen H, Leppla SH. (2000)
Tumor cell-selective cytotoxicity of matrix metalloproteinase-
activated anthrax toxin. Cancer Res. 60, 6061-6067.
57. Thomas G. (2002) Furin at the cutting edge: from protein
traffic to embryogenesis and disease. Nat. Rev. Mol. Cell Biol.
3, 753-766.
58. Goyal A, Batra JK. (2000) Inclusion of a furin-sensitive spacer
enhances the cytotoxicity of ribotoxin restrictocin containing
recombinant single-chain immunotoxins. Biochem. J. 345Pt 2,
247-254.
59. Wang T, Zhao J, Ren JL, Zhang L, Wen WH, Zhang R, et al.
(2007) Recombinant immunoproapoptotic proteins with furin
site can translocate and kill HER2-positive cancer cells.
Cancer Res. 67, 11830-11839.
60. Widera A, Norouziyan F, Shen WC. (2003) Mechanisms of
TfR-mediated transcytosis and sorting in epithelial cells and
applications toward drug delivery. Adv. Drug Deliv. Rev. 55,
1439-1466.
61. Shah D, Shen WC. (1994) The establishment of polarity and
enhanced transcytosis of transferrin receptors in enterocyte-
like Caco-2 cells. J. Drug Target. 2, 93-99.
62. Duttaroy A, Kanakaraj P, Osborn B, Schneider H, Pickeral O,
Chen C, et al. (2005) Development of a long-acting insulin
analog using albumin fusion technology. Diabetes 54,
251-258.
Search WWH ::
Custom Search